SCHEMBL3685034

SCHEMBL3685034

O=C(O)Cc1ccc(S)c(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 2/20 0.65
▸ KDM4E B2RXH2 5/20 0.50
▸ HPGD P15428 4/20 0.50
▸ HSD17B10 Q99714 4/20 0.50
▸ GAA P10253 4/20 0.50
▸ TSHR P16473 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ NFKB1 P19838 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ RGS12 O14924 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ APEX1 P27695 1/20 0.50
▸ THPO P40225 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ GNAI1 P63096 1/20 0.50
▸ PMP22 Q01453 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ ALDH1A1 P00352 4/20 0.46
▸ MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13492126 0.85 CA2 (0.59) CA2KDM4EHPGDHSD17B10GAA
SCHEMBL5338751 0.82 GAA (0.55) CA2KDM4EHPGDHSD17B10GAA
SCHEMBL283587 0.82 CA2 (0.71) CA2KDM4EHPGDHSD17B10GAA
SCHEMBL30021070 0.81 CA2 (0.65) CA2KDM4EHPGDHSD17B10GAA
SCHEMBL5145636 0.81 CA2 (0.65) CA2KDM4EHPGDHSD17B10GAA
Methane SCHEMBL7951771 0.80 CA2 (0.69) CA2KDM4EHPGDHSD17B10GAA
Hydrochloric Acid SCHEMBL2530252 0.80 CA2 (0.69) CA2KDM4EHPGDHSD17B10GAA
SCHEMBL377583 0.79 CYP4F2 (0.53) CA2HPGDGAATSHRMAPT
SCHEMBL11859884 0.78 CA2 (0.67) CA2KDM4EHPGDHSD17B10GAA
Methyl Alcohol SCHEMBL7045180 0.78 CA2 (0.67) CA2KDM4EHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 — — US disclosed
WO-2009096526-A1 CARBOXYLIC ACID COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 — — WO disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 — — US disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 — — EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 — — WO disclosed
EP-0106565-B1 LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THEM MERCK FROSST CANADA INC. (CA) 1986-09-10 — — EP disclosed
EP-0106565-A1 Leukotriene antagonists, their production, and compositions containing them MERCK FROSST CANADA INC. (CA) 1984-04-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG CA2 1679/4885KDM4E 3238/4885HPGD 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback